Rekha Dhanwani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rekha Dhanwani has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
John Pham
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
3 shared publications- Alba Grifoni
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications - Alessandro Sette
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications - Chris A. Benedict
Center for Vaccine Innovation and Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, La Jolla, California, USA
2 shared publications Gaelle Picarda
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
2 shared publicationsJohn Sidney
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
2 shared publications
Latest Publications
- 13 October 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (21) , e0094021
Profiling Human Cytomegalovirus-Specific T Cell Responses Reveals Novel Immunogenic Open Reading Frames
To understand the crucial role of adaptive immunity in controlling cytomegalovirus infection and disease, we systematically analyzed the CMV “ORFeome” to identify new CMV epitopes targeted primarily by CD4 T cells in humans. Our study identified >200 new T cell epitopes derived from both canonical and novel ORFs, highlighting the substantial breadth of the anti-CMV T cell response and providing new targets for vaccine design.
- 13 October 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (21) , e0094021
Profiling Human Cytomegalovirus-Specific T Cell Responses Reveals Novel Immunogenic Open Reading Frames
To understand the crucial role of adaptive immunity in controlling cytomegalovirus infection and disease, we systematically analyzed the CMV “ORFeome” to identify new CMV epitopes targeted primarily by CD4 T cells in humans. Our study identified >200 new T cell epitopes derived from both canonical and novel ORFs, highlighting the substantial breadth of the anti-CMV T cell response and providing new targets for vaccine design.
- Open Access
Profiling Human CMV-specific T cell responses reveals novel immunogenic ORFs
Despite the prevalence and medical significance of human cytomegalovirus (HCMV) infections, a systematic analysis of the targets of T cell recognition in humans that spans the entire genome and includes recently described potential novel ORFs is not available. Here, we screened a library of epitopes predicted to bind HLA class II that spans over 350 different HCMV ORFs and includes ∼150 previously described and ∼200 recently described potential novel ORFs using an ex vivo IFNγ fluorospot assay. We identified 235 unique HCMV specific epitopes derived from 100 ORFs, some previously described as immunodominant and others that were not previously described to be immunogenic. Of those, 41 belong to the set of recently reported novel ORFs, thus providing evidence that at least some of these are actually expressed in vivo in humans. These data reveal that the breadth of the human T cell response to HCMV is much greater than previously thought. The ORFs and epitopes identified will help elucidate how T cell immunity relates to HCMV pathogenesis and instruct ongoing HCMV vaccine research. Importance: To understand the crucial role of adaptive immunity in controlling cytomegalovirus infection and disease, we systematically analyzed the CMV ’ORFeome’ to identify new CMV epitopes targeted primarily by CD4 T cells in humans. Our study identified >200 new T cell epitopes derived from both canonical and novel ORFs, highlighting the substantial breadth of anti-CMV T cell response and providing new targets for vaccine design.
Open AccessProfiling Human CMV-specific T cell responses reveals novel immunogenic ORFs
Despite the prevalence and medical significance of human cytomegalovirus (HCMV) infections, a systematic analysis of the targets of T cell recognition in humans that spans the entire genome and includes recently described potential novel ORFs is not available. Here, we screened a library of epitopes predicted to bind HLA class II that spans over 350 different HCMV ORFs and includes ∼150 previously described and ∼200 recently described potential novel ORFs using an ex vivo IFNγ fluorospot assay. We identified 235 unique HCMV specific epitopes derived from 100 ORFs, some previously described as immunodominant and others that were not previously described to be immunogenic. Of those, 41 belong to the set of recently reported novel ORFs, thus providing evidence that at least some of these are actually expressed in vivo in humans. These data reveal that the breadth of the human T cell response to HCMV is much greater than previously thought. The ORFs and epitopes identified will help elucidate how T cell immunity relates to HCMV pathogenesis and instruct ongoing HCMV vaccine research. Importance: To understand the crucial role of adaptive immunity in controlling cytomegalovirus infection and disease, we systematically analyzed the CMV ’ORFeome’ to identify new CMV epitopes targeted primarily by CD4 T cells in humans. Our study identified >200 new T cell epitopes derived from both canonical and novel ORFs, highlighting the substantial breadth of anti-CMV T cell response and providing new targets for vaccine design.
- Open Access
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba3688
Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response
Metabolic analysis of ADA2-deficient cells shows that extracellular purine nucleosides trigger cellular innate immunity.
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba3688
Open AccessCellular sensing of extracellular purine nucleosides triggers an innate IFN-β response
Metabolic analysis of ADA2-deficient cells shows that extracellular purine nucleosides trigger cellular innate immunity.
- Open Access
- 1 July 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (1) , 84-92
Widespread Tau-Specific CD4 T Cell Reactivity in the General Population
Tau protein is found to be aggregated and hyperphosphorylated (p-tau) in many neurologic disorders, including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury, and even in normal aging. Although not known to produce autoimmune responses, we hypothesized that the appearance of aggregated tau and p-tau with disease could activate the immune system. We thus compared T cell responses to tau and p-tau–derived peptides between PD patients, age-matched healthy controls, and young healthy controls (<35 y old; who are less likely to have high levels of tau aggregates). All groups exhibited CD4+ T cell responses to tau-derived peptides, which were associated with secretion of IFN-γ, IL-5, and/or IL-4. The PD and control participants exhibited a similar magnitude and breadth of responses. Some tau-derived epitopes, consisting of both unmodified and p-tau residues, were more highly represented in PD participants. These results were verified in an independent set of PD and control donors (either age-matched or young controls). Thus, T cells recognizing tau epitopes escape central and peripheral tolerance in relatively high numbers, and the magnitude and nature of these responses are not modulated by age or PD disease.
- 1 July 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (1) , 84-92
Open AccessWidespread Tau-Specific CD4 T Cell Reactivity in the General Population
Tau protein is found to be aggregated and hyperphosphorylated (p-tau) in many neurologic disorders, including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury, and even in normal aging. Although not known to produce autoimmune responses, we hypothesized that the appearance of aggregated tau and p-tau with disease could activate the immune system. We thus compared T cell responses to tau and p-tau–derived peptides between PD patients, age-matched healthy controls, and young healthy controls (<35 y old; who are less likely to have high levels of tau aggregates). All groups exhibited CD4+ T cell responses to tau-derived peptides, which were associated with secretion of IFN-γ, IL-5, and/or IL-4. The PD and control participants exhibited a similar magnitude and breadth of responses. Some tau-derived epitopes, consisting of both unmodified and p-tau residues, were more highly represented in PD participants. These results were verified in an independent set of PD and control donors (either age-matched or young controls). Thus, T cells recognizing tau epitopes escape central and peripheral tolerance in relatively high numbers, and the magnitude and nature of these responses are not modulated by age or PD disease.